

## Treatment for Myelofibrosis

---

Reference Number: F4582  
Date of Response: 26/08/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

### **Request and Royal Devon's Eastern FOI Office Response**

Q1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?

**The Trust treats Myelofibrosis locally. Myelofibrosis patients are only referred to the transplant centre if an allogenic stem cell transplant is to be considered.**

Q2. (A) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).

**A total of 25 patients were treated within the past 6 months for Myelofibrosis.**

b) How many of these patients were above age 65?

**20 of these patients were above the age of 65.**

Q3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?

**Within the past 6 months, a total of 12 patients were treated using Ruxolitinib.**

Q4. (A) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

**Within the past 3 years, the Trust has diagnosed 70 patients with Myelofibrosis.**

b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:

- Received No Treatment

**Within the past 6 months, of these patients, 40 patients haven't been administered any medication. However, we are unable to say for definite that they haven't received any other forms of treatment.**

**In accordance with section 40 (2) of the Freedom of Information Act 2000, We are unable to provide the figures for the following treatments:**

- Hydroxyurea
- Fedratinib

We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and principle One of the GDPR.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

The Trust currently has one active trial which is MITHRIDATE.

The Trust can confirm that it holds the data relating to the amount of patients taking part in this trial, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and principle One of the GDPR.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.